Department of Internal Medicine, Eisenhower Health, Rancho Mirage, CA, USA.
Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA, USA.
J Oncol Pharm Pract. 2021 Mar;27(2):453-456. doi: 10.1177/1078155220929967. Epub 2020 Jun 6.
Clinical indications of immune checkpoint inhibitors have expanded to a variety of malignancies. Approximately one in six patients with hepatocellular carcinoma respond to programmed death 1 inhibitors nivolumab and pembrolizumab.
We report herein a patient with synchronous metastatic hepatocellular carcinoma and advanced papillary thyroid carcinoma treated with nivolumab in the second-line therapy.Management and outcome: The hepatocellular carcinoma showed a durable response to the second-line agent nivolumab. Remarkably, the patient's papillary thyroid carcinoma also responded to this programmed death 1 inhibitor.
To our knowledge, this is the first case report showing the efficacy of nivolumab in the treatment of metastatic papillary thyroid carcinoma. Further studies with immune checkpoint inhibitors in papillary thyroid carcinoma seem warranted.
免疫检查点抑制剂的临床适应证已扩展到多种恶性肿瘤。大约六分之一的肝细胞癌患者对程序性死亡 1 抑制剂纳武利尤单抗和帕博利珠单抗有反应。
我们在此报告了一例同时患有转移性肝细胞癌和晚期甲状腺乳头状癌的患者，该患者接受二线治疗纳武利尤单抗治疗。
肝细胞癌对二线药物纳武利尤单抗显示出持久的反应。值得注意的是，患者的甲状腺乳头状癌也对这种程序性死亡 1 抑制剂有反应。
据我们所知，这是首例报告显示纳武利尤单抗在治疗转移性甲状腺乳头状癌中的疗效。进一步研究免疫检查点抑制剂在甲状腺乳头状癌中的作用似乎是必要的。
